Clinical Trial Update: Safety, Efficacy and Pharmacokinetics of Subcutaneous ACZ885 in Patients With Systemic Juvenile Idiopathic Arthritis (SJIA) [Phase 1, Phase 2]

View source ↗

Summary

This completed Phase 1/2 study assessed the safety, efficacy and pharmacokinetics of subcutaneous ACZ885 (canakinumab) in patients with systemic juvenile idiopa…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Systemic Juvenile Idiopathic Arthritis

Drugs mentioned

• ACZ885 (canakinumab)

Snippet

Sponsor: Novartis | Conditions: Arthritis, Juvenile Rheumatoid | Phase 1, Phase 2 | Status: COMPLETED